Announcements & Publications News Goldilocks CEO Arthur Klausner was interviewed on February 10, 2020 at the BIO CEO conference in New York City Mesoscale nanoparticle technology shown to be effective in a mouse model of ischemic acute kidney injury Presentations Goldilocks CEO Arthur Klausner presented at the BIO CEO conference in New York City on February 12, 2020. The slide deck can be found here. Scientific Articles Edaravone-Loaded Mesoscale Nanoparticles Treat Cisplatin-Induced Acute Kidney Injury (2020) Selective Nanoparticle Targeting of the Renal Tubules (2018) Mesoscale Nanoparticles – An Unexpected Means for Selective Therapeutic Targeting of Kidney Diseases! (2018) Nanomedicines for Kidney Diseases (2016) Mesoscale Nanoparticles Selectively Target the Renal Proximal Tubule Epithelium (2015) Posters Mesoscale Nanoparticles Treat Cisplatin-Induced Acute Kidney Injury and Avoid Tumor Accumulation (2019 American Society of Nephrology Annual Meeting) Renal Selective Mesoscale Nanoparticles Treat Cisplatin-Induced Acute Kidney Injury Treatment of Acute Kidney Injury with Kidney Targeting Mesoscale Nanoparticles (2018 Annual Meeting of the Controlled Release Society) Mesoscale Nanoparticles Selectively and Safely Target the Renal Proximal Tubules (2017 American Society of Nephrology Annual Meeting) Renal Selective Mesoscale Nanoparticles Treat Cisplatin-Induced Acute Kidney Injury (2017 American Society of Nephrology Annual Meeting)
